Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer

Current Opinion in Oncology

Volumn 22, Issue 2, 2010, Pages 112-120

  Rosell, Rafael ^a,b   Viteri, Santiago ^b   Molina, Miguel Angel ^b   Benlloch, Susana ^b   Taron, Miquel ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b INSTITUT UNIVERSITARI DEXEUS   (Spain)

Author keywords

Epidermal growth factor receptor mutations; Nonsmall cell lung cancer; Serum DNA; Threonine at position 790

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C RECEPTOR;

CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MECHANISM; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SCREENING; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 76749137179     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32833500d2     Document Type: Review

References (48)

1. Gazdar AF. Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med 2009; 361:1018-1020.
2. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate antiapoptotic pathways. Science 2004; 305:1163-1167.
3. Inoue A, Kobayashi K, Usui K, et al. First-line gefitinib for patients with advanced nonsmall-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009; 27:1394-1400.
4. Linardou H, Dahabreh IJ, Bafaloukos D, et al. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol 2009; 6:352-366.
5. Bai H, Mao L, Wang HS, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV nonsmall-cell lung cancer. J Clin Oncol 2009; 27:2653-2659.
6. Tam IY, Leung EL, Tin VP, et al. Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. Mol Cancer Ther 2009; 8:2142-2151.
7. Chitale D, Gong Y, Taylor BS, et al. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene 2009; 28:2773-2783.
8. Schmid K, Oehl N, Wrba F, et al. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 2009; 15:4554-4560.
9. Costa DB, Nguyen KS, Cho BC, et al. Effects of erlotinib in EGFR mutated nonsmall cell lung cancers with resistance to gefitinib. Clin Cancer Res 2008; 14:7060-7067.
10. Ichihara E, Ohashi K, Takigawa N, et al. Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. Cancer Res 2009; 69:5091-5098.
11. Jackman DM, Miller VA, Cioffredi LA, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated nonsmall cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009; 15:5267-5273.
12. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced nonsmall-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008; 26:2442-2449.
13. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with nonsmall cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006; 12:839-844.
14. Morita S, Okamoto I, Kobayashi K, et al. Combined survival analysis of prospective clinical trials of gefitinib for nonsmall cell lung cancer with EGFR mutations. Clin Cancer Res 2009; 15:4493-4498.
15. Gandhi J, Zhang J, Xie Y, et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS ONE 2009; 4:e4576.
16. Mounawar M, Mukeria A, Le Calvez F, et al. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in nonsmall cell lung cancers in relation to smoking history. Cancer Res 2007; 67:5667-5672.
17. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361:958-967.
18. MokTS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957.
19. Seike M, Goto A, OkanoT, et al. MiR-21 is an EGFR-regulated antiapoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci USA 2009; 106:12085-12090.
20. Meng F, Henson R, Wehbe-JanekH, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133:647-658.
21. Kuang Y, Rogers A, Yeap BY, et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant nonsmall cell lung cancer. Clin Cancer Res 2009; 15:2630-2636.
22. Chin TM, Quinlan MP, Singh A, et al. Reduced erlotinib sensitivity of epidermal growth factor receptor-mutant nonsmall cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment. Clin Cancer Res 2008; 14:6867-6876.
23. Das AK, Sato M, Story MD, et al. Nonsmall-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res 2006; 66:9601-9608.
24. Das AK, Chen BP, Story MD, et al. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in nonsmall cell lung carcinoma. Cancer Res 2007; 67:5267-5274.
25. Rosell R, Perez-Roca L, Sanchez JJ, et al. Customized treatment in nonsmall-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS ONE 2009; 4:e5133.
26. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009; 10:281-289.
27. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008; 359:366-377
28. Inukai M, Toyooka S, Ito S, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in nonsmall cell lung cancer. Cancer Res 2006; 66:7854-7858.
29. Wang B, Matsuoka S, Ballif BA, et al. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 2007; 316:1194-1198.
30. Wu X, Mondal G, Wang X, et al. Microcephalin regulates BRCA2 and Rad51-associated DNA double-strand break repair. Cancer Res 2009; 69:5531-5536.
31. Livingston DM. Cancer. Complicated supercomplexes. Science 2009; 324:602-603.
32. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123-134.
33. Li D, Ambrogio L, Shimamura T, et al. BIBW2992,an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008; 27:4702-4711.
34. Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008; 118:2609-2619.
35. Wolf I, Levanon-Cohen S, Bose S, et al. Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene 2008; 27:7094-7105.
36. Gao SP, Mark KG, Leslie K, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007; 117:3846-3856.
37. Rosell R, Bertran-Alamillo J, Molina MA, Taron M. IL-6/gp130/STAT3 signaling axis in cancer and the presence of in-frame gp130 somatic deletions in inflammatory hepatocellular tumors. Future Oncol 2009; 5:305-308.
38. Morgillo F, Woo JK, Kim ES, et al. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006; 66:10100-10111.
39. Scott KL, Kabbarah O, Liang MC, et al. GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature 2009; 459:1085-1090.
40. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299:425-436.
41. Cortez MA, Calin GA. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther 2009; 9:703-711.
42. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
43. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500.
44. PaoW,MillerV,ZakowskiM,etal. EGF receptorgenemutations arecommon in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101:13306-13311.
45. Taron M, Ichinose Y, Rosell R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005; 11:5878-5885.
46. Smouse JH, Cibas ES, Janne PA, et al. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer Cytopathol 2009; 117:67-72.
47. Molina-Vila MA, Bertran-Alamillo J, Reguart N, et al. A sensitive method for detecting EGFR mutations in nonsmall cell lung cancer samples with few tumor cells. J Thorac Oncol 2008; 3:1224-1235.
48. Miyazawa H, Tanaka T, Nagai Y, et al. Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation.Cancer Sci 2008; 99:595-600.